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Naturally, such research would include replication of 
Ennis and colleagues’ results in large independent 
cohorts as well as functional studies. A point to keep 
in mind is that Ennis chieﬂ y investigated HapMap tag 
SNPs in SERPING1, with the idea that these SNPs serve 
as a proxy for the causal variants in the presence of 
strong linkage disequilibrium across the region. This 
assumption might not hold true in all populations. In 
view of potential diﬀ erences in linkage disequilibrium, 
these tag SNPs might not always adequately represent 
the disease risk of non-examined variants in the gene, 
which is a particular concern when causal SNPs are rare 
or have small eﬀ ects.
Therefore a logical next step would be to search 
for true susceptibility alleles. SERPING1 is located on 
chromosome 11q12-13.1 and is a moderately sized gene 
with eight exons that span 17 kb. Mutations in this gene 
are the primary cause of hereditary angioedema.11 The 
mutation spectrum is large for this disease; the mutations 
include missense, nonsense, and splice-site mutations, 
and they reside in almost all exons.10 More common 
disease-associated variants in SERPING1 have not been 
described extensively. One of the few common missense 
variants in the coding region, rs4926 or V480M, which 
is associated with nasal carriage of Staphylococcus aureus, 
has already been excluded.12 The gene harbours a total of 
65 SNPs according to public databases, of which 18 could 
have a functional eﬀ ect on coding or regulation of the 
protein.13,14
Examination of SNPs such as these as well as 
sequencing of a suitable surrounding interval, including 
the coding region, in a large group of well-deﬁ ned cases 
and controls will help identify variants with functional 
implications, and further establish SERPING1 as a true 
risk factor for age-related macular degeneration.
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On Sept 16, UK television’s Channel 4 News featured an 
“exclusive” and “shocking” report that, after positive 
serum or ultrasound screening for Down’s syndrome, 
diagnostic testing by amniocentesis or chorionic villus 
sampling results in two healthy babies being miscarried 
for every three Down’s syndrome births prevented.1 
The ﬁ ndings (published early online to coincide with 
the broadcast) are from an editorial by Frank Buckley 
and Sue Buckley, Chief Executive and Chief Scientist 
of Down Syndrome Education International (DSEI), 
respectively, in Down Syndrome Research and Practice.2 
In this editorial, data from the National Down’s 
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Syndrome Cytogenetic Register (NDSCR)3 on prenatal 
and postnatal diagnoses of Down’s syndrome and on 
terminations were analysed; fetal losses in pregnancies 
unaﬀ ected by Down’s syndrome were estimated by 
statistical modelling because national data on losses 
in non-aﬀ ected pregnancies were not available. The 
editorialists used the ﬁ ndings to query whether prenatal 
screening for Down’s syndrome was justiﬁ able. The 
editorial was circulated widely to the mass media and 
to international Down’s syndrome associations.4
We write as researchers and advocates for people with 
Down’s syndrome and their families, but are also sensitive 
to the views of prospective parents and welcome 
wider engagement in the social debate about prenatal 
screening for this condition. We also acknowledge the 
widely respected educational and advocacy work of 
DSEI. However, our concern is that in using an editorial 
to disseminate new interpretations of existing datasets, 
the independent assessment for scholarly integrity that 
is the hallmark of peer review has been bypassed. The 
recognised pathway is to submit such work to a peer-
reviewed academic journal as a research article.
Three drafts of the editorial were sent for comment to 
the 34-member editorial board of the journal between 
July 24 and Sept 16. Both process and timescale were 
immediately queried. 14 members had responded to the 
board’s listserver by the online publication date; eight 
directly addressed the scientiﬁ c content, expressing 
concerns about its clarity and editorial status and 
pressing for external reviews. Three external reviewers 
of early drafts were named and copies of comments 
from two provided. On Aug 19, the board was told 
that “six external experts were to review the latest 
draft, including ﬁ ve experts in UK prenatal screening 
practice and statistics”5 but was then informed that 
these reviews could not be shared on “conﬁ dentiality” 
grounds or because comments had been by telephone.6
In view of the importance and complexity of the topic 
addressed, the editorial would have beneﬁ ted from 
an independent review process, especially in respect 
of the literature selected on screening and on Down’s 
syndrome, and the model used to calculate fetal loss 
rates. For example, for fetal loss rates, the editorial states 
that “the best available evidence suggests that the risk 
of pregnancy loss due to amniocentesis is 1%...and [for] 
chorionic villus sampling (CVS) is 2%” and the authors 
maintain they have been “cautious” in applying a 1% 
loss rate in their modelling of outcomes for pregnancies 
aﬀ ected and unaﬀ ected by Down’s syndrome.2 The 
quoted loss levels are similar to those ﬁ rst established 
in the 1980s, when both procedures were still relatively 
new.7,8 Recent research indicates lower risk, conservatively 
1 in 200–300, with little diﬀ erence between the two 
procedures when performed skilfully and when indi-
vidual obstetric risk factors are considered.9–12
The editorial’s claim for a 25% increase in livebirths 
aﬀ ected by Down’s syndrome, derived from NDSCR 
data, is similarly questionable. NDSCR has recorded all 
Down’s syndrome diagnoses in England and Wales since 
1989, with its most recent report covering 1989–2006 
(ﬁ gure).3 The editorial selected data from 1992–2006 
for analysis, modelled missing data for outcomes, 
and concluded that the number of livebirths was “up 
25% over 15 years”.2 However, had the 10-year period 
1997–2006 been selected instead, this headline ﬁ gure 
would have been 10·5%.
On a broader front, the editorial also failed to consider 
adequately the views of pregnant women, recent 
advances in screening eﬃ  ciency, and what might be 
argued to be some of the more positive aspects of 
screening. Many parents wish to be screened: some to 
reduce the stress of waiting, some to be prepared for 
unplanned outcomes, and some in case they might 
wish to consider a termination. Improved methods have 
reduced the number of invasive tests required at older 
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Figure: Number of livebirths aﬀ ected by Down’s syndrome in England and Wales, 1989–2006
NDSCR data; ﬁ gure for 2006 is provisional.3
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maternal ages, the percentage of false positives, and the 
number of invasive diagnostic tests required for each 
case identiﬁ ed.13 First-trimester non-invasive diagnostic 
testing may be available within 5–10 years.14
Prenatal screening is of major scientiﬁ c and clinical 
interest, and potentially aﬀ ects 650 000 women per year 
in the UK alone. Published as an editorial, and without 
independent peer review, the analysis lacks the necessary 
authority to assist people in making personal decisions 
about screening and diagnosis, including families who 
already have a child with Down’s syndrome. It also 
distracts attention from the need for increased funding 
for Down’s syndrome research and for reassessment of 
research priorities within this ﬁ eld.15
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China’s HIV/AIDS epidemic: continuing challenges
In 2007, China estimated that there were about 
700 000 residents infected with HIV and that 
85 000 people had AIDS.1,2 Although the prevalence 
of HIV infection as a whole was about 0·05%, each 
of several provinces (including Yunnan, Guangxi, 
Guangdong, Xinjiang, and Henan) had high numbers 
of infected people (>30 000).2 Most cases of HIV 
infection are in injection drug users, men who have sex 
with men, sex workers, and in infected blood donors 
who survived the HIV epidemic in rural China during 
the mid-1990s. The rural focus of the HIV epidemic 
and low levels of sexual mixing might have prevented 
a rapid spread, but sexual behaviours are rapidly 
changing.
Although slow to acknowledge the epidemic since 
2003, China has made considerable changes to its 
policies by implementation of innovative strategies and 
setting up of a comprehensive anti-HIV programme. 
The objective is to control spread beyond the major risk 
groups.3,4 But some of the issues remain to be resolved.
The weak infrastructure of health care implies that the 
goal of providing treatment for all in need will be diﬃ  cult, 
especially in rural areas where most infections occur. 
Development of drug resistance and toxic eﬀ ects require 
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